The global blood market size was valued at USD 9.4 billion in 2025 and is projected to grow from USD 9.89 billion in 2026 to USD 14.79 billion by 2034 at a CAGR of 5.16% during the forecast period 2026-2034.
Blood is a specialized and essential body fluid that comprises four major components, i.e., plasma, platelets, RBCs, and WBCs. Each component plays a vital role in various diagnostics and therapeutic applications, particularly for patients suffering from blood-related disorders such as cardiovascular diseases, cancer, and hematological conditions. This wide-ranging applicability fuels the growth of the global market.
Furthermore, the rising prevalence of trauma, accidents, and surgeries necessitates an increased demand for blood products. The surge in surgical procedures, combined with the growing incidences of trauma and chronic diseases, significantly contributes to the expanding market. Advancements in medical technologies, such as processing automation and storage systems, are also improving the safety and efficiency of RBC transfusions.
Automation in the processing of whole blood significantly enhances operational efficiency by smoothening every step from collection to distribution. Automated systems also reduce human interventions, resulting in the minimization of errors and inconsistencies that humans can cause. These systems also ensure high consistency and precision in blood processing by automating tasks such as separation, filtration, and storage.
The trend towards personalized blood products in the market reflects a growing patient need according to individual needs, such as resembling particular cell types and immune profiles to gain therapeutic outcomes on a long-term basis.
As patients increasingly seek long-term solutions, personalized RBC products provide more precise and effective treatments. This indicates a broader shift towards precision medicine, aiming for better health outcomes based on individualized care.
Download Free Sample Report to Get Detailed Insights.
The growing prevalence of blood-related disorders, such as cancer, is significantly driving the demand for RBC and RBC components. With an increasing number of individuals diagnosed with conditions requiring transfusions, including cancer, trauma, and surgical procedures, the need for blood products continues to rise. The demand is particularly strong for RBCs, plasma, and platelets, which are crucial in managing such conditions.
Technological advancements are accelerating the growth of the blood market by improving the accuracy and efficiency of RBC transfusions and related treatments. Innovations, such as mobile blood testing technology, are enhancing traceability and reducing human error during vital procedures.
These improvements not only increase patient trust but also encourage further investment in the sector.
The high cost of blood collection, processing, and screening is a significant barrier to the widespread availability and utilization of RBC products, particularly in healthcare facilities with limited budgets. This high cost restricts the ability to implement advanced technologies for blood collection and testing, impacting the overall efficiency of blood banks and hospitals. Moreover, the cost of RBC screening for infections further complicates the process, adding financial strain to both healthcare providers and patients.
There is a growing opportunity to address the demand for blood transfusions in rural areas, where access to medical facilities and hematic fluid transfusion services is often limited. With more people migrating to urban centers, rural regions face an increasing need for efficient hematic fluid delivery solutions. Innovative approaches such as drone-based blood delivery, intraoperative autotransfusions, and mobile blood banks could significantly improve access to hematic fluid in these underserved areas.
Whole blood collection and processing segment dominates the market with the highest market revenue
The whole blood collection and processing segment leads the market due to the widespread applications of whole blood in treating chronic conditions like hematological disorders, kidney disease, and trauma-related blood loss. Whole blood is also essential for transfusions, especially in cancer treatment, surgical procedures, and emergencies.
Blood and blood component bank segment dominates the market with the highest market revenue
The blood and blood component bank segment holds the largest blood market share by end users, driven by the critical role these facilities play in ensuring the availability and storage of blood in optimal conditions for future use. Blood banks not only store whole blood but also plasma, platelets, and other components, which are essential for a variety of medical treatments, including surgeries, cancer care, and trauma management. These facilities also facilitate key processes such as hematic fluid collection, screening, and processing, ensuring the safety and efficacy of hematic fluid products.
North America holds a dominant position in the global market, driven by advanced technologies in blood processing, screening, and blood-related devices that enhance clinical development for treating chronic illnesses. The region is at the forefront of innovations aimed at improving the efficiency and safety of blood transfusions and therapies derived from blood components. These innovations accelerate the clinical development of therapies used in managing conditions like cancer, anemia, and trauma recovery.
Moreover, ongoing research and development in creating new blood-based treatments for various diseases contribute to the region's strong market share. As North American healthcare institutions continue to invest in cutting-edge technologies, such as automated hematic fluid screening and artificial blood substitutes, the region is expected to maintain its leadership.
The Asia-Pacific region is witnessing the fastest growth in the global market, driven by a rising incidence of chronic illnesses like cancer, hemophilia, and immune deficiencies. This surge in demand for hematic fluid and derived products is shaping the future of the market in the region.
This increasing cancer burden significantly boosts the need for hematic fluid components such as platelets and plasma for treatment. As healthcare infrastructure improves across Asia-Pacific countries, the demand for blood transfusions and related treatments continues to grow, spurring the development of blood banks, donation camps, and modern blood processing techniques.
The market is experiencing dynamic growth and diversification across the globe, with each country contributing uniquely to the advancement of this transformative field. Below are a few countries that illustrate the diverse contributions and advancements in the blood industry.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com